Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Reem Karmali, Franck Morschhauser, Koji Izutsu, Lia Palomba, Kirit Ardeshna, Brian Hill, Manali Kamdar, Stephen J. Schuster, Antonio Pinto, Saurabh Dahiya, Merav Bar, Maria Strocchia, Jinender Kumar, Jeremy Abramson

Blood (2025) 146 (Supplement 1): 709.

https://doi.org/10.1182/blood-2025-709

Published: 2025

Journal Articles

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Blood (2025) 146 (Supplement 1): 467.

https://doi.org/10.1182/blood-2025-467

Published: 2025

Journal Articles

Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia

Pramila Krishnamurthy, Katherine Houghton, Nicola Lorenz, Paula Williams, Lisa Currie, Carlos E. Vigil, Nomthandazo Ziba, Fareedat Bello, Jan Sieluk, Maria Strocchia, Yeran Li, Silke Kapp-Schwoerer

Blood (2024) 144 (Supplement 1): 2425.

https://doi.org/10.1182/blood-2024-198362

Published: 2024

Journal Articles

Intensive Chemotherapy (IC) Followed By Oral Azacitidine (AZA) Maintenance Versus Venetoclax (VEN) Plus AZA for Patients (pts) with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Record (EMR) Database in the United States

Alice Mims, Zhuoer Xie, Alberto Vasconcelos, Maria Strocchia, Lona Gaugler, Sara Vergara, Ying Qiu, David Rotter, Ravi Potluri, Thomas Prebet, Jan Sieluk

Blood (2023) 142 (Supplement 1): 550.

https://doi.org/10.1182/blood-2023-173442

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia

Intensive Chemotherapy (IC) Followed By Oral Azacitidine (AZA) Maintenance Versus Venetoclax (VEN) Plus AZA for Patients (pts) with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Record (EMR) Database in the United States

Email alerts

ASH Publications

American Society of Hematology

Update search

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia

Intensive Chemotherapy (IC) Followed By Oral Azacitidine (AZA) Maintenance Versus Venetoclax (VEN) Plus AZA for Patients (pts) with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Record (EMR) Database in the United States

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only